All Stories

  1. Automatic metabolic breast cancer staging using [¹⁸F]FDG PET/CT: comparison with nuclear medicine physician-based and clinical staging
  2. An AI-Based Solution for Denoising Fast-Acquisition [18F]FDG PET: Clinical Feasibility and Quantitative Assessment
  3. WRONG journal! It should be "European Journal of Nuclear Medicine and Molecular Imaging"
  4. Striatal dopamine D2-like receptors availability in obesity and its modulation by bariatric surgery: a systematic review and meta-analysis
  5. Targeted radionuclide therapy directed to the tumor phenotypes: A dosimetric approach using MC simulations
  6. An Optimized Methodology for Patient-Specific Therapeutic Activity Administration in Liver Radioembolization
  7. Patlak plot based on the first 30 minutes post-injection dynamic 18F-florbetaben positron emission tomography scan separates amyloid-β positive from negative studies
  8. Brain [18F]Fluorodeoxyglucose Metabolism Assessment under Hypothyroidism and Recombinant Human Thyroid-Stimulating Hormone in Comparison with Thyroid Hormone Replacement in Patients Submitted to Total Thyroidectomy
  9. Positron Emission Tomography–Derived Metrics Predict the Probability of Local Relapse After Oligometastasis-Directed Ablative Radiation Therapy
  10. Las relaciones de ventilación/perfusión corregidas por píxeles mejoraron la detección de defectos de perfusión no coincidentes
  11. PSMA expression in thyroid nodule
  12. 123I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease: a new quantitative analysis of autopsy confirmed cases
  13. Are lesion features reproducible between 18F-FDG PET/CT images when acquired on analog or digital PET/CT scanners?
  14. Asymptomatic COVID-19 positive patient suspected on FDG-PET/CT
  15. Negative affect and stress‐related brain metabolism in patients with metastatic breast cancer
  16. Principles and Constraints of Nonrigid Registration
  17. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients
  18. Phenotype-Oriented Ablation of Oligometastatic Cancer with Single Dose Radiation Therapy
  19. Using 3D anthropometric data for the modelling of customised head immobilisation masks
  20. Segmentation of pathological liver tissue with Dilated Fully Convolutional Networks: A Preliminary Study
  21. Evaluation of the attenuation correction on myocardial perfusion imaging: a phantom study
  22. Voxel-Based Computational Tools Help Liver Dosimetry Calculations of Multiple (External and Internal) Radiation Therapies
  23. Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT
  24. Comparison of the 90Y-labelled glass microspheres liver radioembolisation dosimetry with the estimated dosimetry obtained from pre-treatment 99mTc-MAA SPECT images reconstructed with and without attenuation correction
  25. Radiopharmacology and molecular imaging of PD-L1 expression in cancer
  26. Patient-specific gamma-index analysis to evaluate 99mTc-MAA as a predictor for 90Y glass microspheres liver radioembolisation dosimetry
  27. Activity estimation and biokinetic analysis of 99mTc-DMSA in renal infant patients using a gamma camera
  28. Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson’s disease based on [123I]FP-CIT SPECT images
  29. Radioembolization with 90Y-Labeled Glass Microspheres: Analytical Methods for Patient-Personalized Voxel-Based Dosimetry
  30. The Importance of SPECT Imaging Attenuation Correction During Treatment Planning for 90Y-labeled Glass Microspheres Liver Radioembolization
  31. 18F-FDG Uptake in Ischemic Colitis During Follow-up of a Patient With Lung Cancer
  32. Gamma-index and dose-volume histograms (based on voxel dosimetry) to evaluate the predictive power of 99mTc-MAA SPECT maps in comparison with post-radioembolization 90Y PET maps
  33. Nuclear Medicine in Oncology
  34. Effect of reconstruction processing methods and analysis in the quantification of brain spect studies with DaTSCAN™
  35. Optimization of activity and absorbed doses calculation to target/tumor and normal liver volumes in patients submitted to yttrium-90 radioembolization with glass microspheres
  36. Nuclear medicine training in the European Union: 2015 update
  37. The influence of number of counts in the myocardium in the determination of reproducible functional parameters in gated-SPECT studies simulated with GATE
  38. Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS)
  39. Predicting conversion from MCI to AD with FDG-PET brain images at different prodromal stages
  40. Analysis of gated myocardial perfusion spect images based on computational image registration
  41. Estimation of the collective ionizing dose in the Portuguese population for the years 2011 and 2012, due to nuclear medicine exams
  42. Ideas from the second UEMS conference on CME/CPD: new EU directives on a patients’ rights in cross-border healthcare and professional qualifications
  43. Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging
  44. FDG gated cardiac PET at rest and immediately after dobutamine stress
  45. Monte Carlo simulation of the basic features of the GE Millennium MG single photon emission computed tomography gamma camera
  46. The new UEMS-EACCME criteria for accreditation of live educational events (LEEs): another step forward to improve the quality of continuing medical education (CME) in Europe
  47. Phenotypes of myocardial blood perfusion related to the genetic variations of metalloproteinases 3 (MMP3) and 9 (MMP9)
  48. Texton-based diagnosis of Alzheimer's disease
  49. Image quality of myocardial perfusion-gated studies: effect of ingestion of different fat content in the reduction of extra-myocardial abdominal signal
  50. Left ventricular function influenced byMMP3gene 5A/6A polymorphism (rs3025058): a gated-SPECT study
  51. Continuing Medical Education Committee and UEMS-EACCME
  52. UEMS/EBNM endeavour – celebrations keep going!
  53. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT
  54. 3D brain image-based diagnosis of Alzheimer's disease: Bringing medical vision into feature selection
  55. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease?
  56. Syllabus for Postgraduate Specialization in Nuclear Medicine – 2011/2012 Update
  57. UEMS/EBNM endeavour
  58. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [123I]FP‐CIT SPECT
  59. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy
  60. [123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease
  61. Applications of PET–CT in clinical practice: Present and future
  62. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
  63. Clinical evaluation of 2D versus 3D whole-body PET image quality using a dedicated BGO PET scanner
  64. Parkinsonism due to Kernohan notch: Clinical, structural, and functional imaging correlates
  65. Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18 FDG and 18 FLT PET
  66. L‐dopa–responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings
  67. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease
  68. Clinical audit in nuclear medicine
  69. Comparison of methodologies for the in vivo assessment of 18 FLT utilisation in colorectal cancer
  70. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP‐CIT/SPECT study
  71. Frontal lobe dysfunction in sporadic hyperekplexia
  72. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography
  73. Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging
  74. Corrections
  75. Potential impact of [ 18 F]3'-deoxy-3'-fluorothymidine versus [ 18 F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer
  76. Positron emission and computed X-ray tomography: a coming together
  77. [123I]‐FP‐CIT‐SPECT demonstrates dopaminergic deficit in orthostatic tremor
  78. In vivo Dopamine Pre-Synaptic Receptors and Antioxidant Activities in Patients with Alzheimer’s Disease, Dementia with Lewy Bodies and in Controls
  79. [ 123 I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia
  80. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET
  81. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study
  82. Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrerʼs perspective
  83. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand
  84. Nuclear Medicine in Primary Breast Cancer Imaging
  85. Typical antipsychotic drugs — D2 receptor occupancy and depressive symptoms in schizophrenia
  86. Can ROI methodology/normalised tissue activities be used instead of absolute blood flow measurements in the brain?
  87. Glucose Utilisation and Cell Proliferation in Colorectal Cancer
  88. Dopamine neurotransmission, Parkinson’s disease and SPET
  89. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders
  90. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer
  91. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET
  92. PET e SPECT em neurologia e psiquiatria: do básico às aplicações clínicas
  93. Functional imaging of malignant paragangliomas and carcinoid tumours
  94. Clinical role of positron emission tomography in oncology
  95. Functional imaging as an aid to decision-making in metastatic paraganglioma
  96. Asymptomatic patient with an increasing concentration of CEA
  97. Positron emission tomography and colorectal cancer
  98. SPECT imaging of the dopamine transporter in juvenile-onset dystonia
  99. A SPECT study of the effect of vagal nerve stimulation on thalamic activity in patients with epilepsy
  100. Levels of γ‐Aminobutyric Acid‐Benzodiazepine Receptors in Abstinent, Alcohol‐Dependent Women: Preliminary Findings From an 123I‐Iomazenil Single Photon Emission Tomography Study
  101. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group
  102. Patterns of brain activity in patients with epilepsy and depression
  103. Nuclear medicine in neurology and psychiatry
  104. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies
  105. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine
  106. Crisis after angiography: time for MIBG
  107. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine
  108. Early detection of melanoma metastases with radioiodinated methylene blue
  109. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS.
  110. Reduced levels of GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy
  111. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study
  112. Recurrent follicular carcinoma-oxyphilic cell type (Hürthle cell carcinoma) of the thyroid, imaging with iodine-131 and technetium-99m tetrofosmin before and after radiotherapy.
  113. Relationship Between SPECT Scans and Buspirone Tests in Patients with ME/CFS
  114. Wisconsin Card Sorting Task (WCST) errors and cerebral blood flow in obsessive‐compulsive disorder (OCD)
  115. Brain blood flow in anxiety disorders
  116. Serotonin: 5-HT2A receptor occupancy in vivo and response to the new antipsychotics olanzapine and sertindole
  117. Limbic selectivity of clozapine
  118. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography
  119. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography
  120. Initial evaluation of123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects
  121. HMPAO SPET does not distinguish obsessive–compulsive and tic syndromes in families multiply affected with Gilles de la Tourette's syndrome
  122. Psychiatric profiles and patterns of cerebral blood flow in focal epilepsy: interactions between depression, obsessionality, and perfusion related to the laterality of the epilepsy.
  123. Thrombosis and restenosis after peripheral angioplasty: Does acute 111indium-platelet accumulation predict angioplasty outcome?
  124. In vivo effects on striatal dopamine D 2 receptor binding by the novel atypical antipsychotic drug sertindole - a 123 I IBZM single photon emission tomography (SPET) study
  125. Caudate regional cerebral blood flow in obsessive-compulsive disorder, panic disorder and healthy controls on single photon emission computerised tomography
  126. Initial evaluation of123|-5-|-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects
  127. Multivariate cluster analysis of dynamic iodine-123 iodobenzamide SPET dopamine D2 receptor images in schizophrenia
  128. 5-HT2A receptor blockade in vivo in schizophrenic patients treated with atypical antipsychotics: Single photon emission tomography (SPET) findings
  129. Multivariate cluster analysis of dynamic [I-123]-IBZM spet dopamine D2 receptor images in schizophrenia
  130. Non-invasive measurement of left ventricular volumes and function by gated positron emission tomography
  131. Radioiodinated methylene blue for diagnosing early melanoma metastases
  132. HMPAO SPECT in non-epileptic seizures: preliminary results
  133. The significance of increased 111indium platelet accumulation at post-angioplasty sites
  134. Polycythaemia and agoraphobia
  135. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a123 IBZM single photon emission tomography (SPET) study
  136. Pathophysiology of Chronic Left Ventricular Dysfunction
  137. Baseline Left Ventricular (LV) performance and functional recovery after revascularisation: Predictive value of absolute 18F Fluorodeoxyglucose (FDG) uptake
  138. Targeting Disseminated Melanoma with Radiolabelled Methylene Blue: Comparative bio-distribution studies in man and animals
  139. Brainstem perfusion is impaired in chronic fatigue syndrome
  140. Regional Cerebral Blood Flow in Obsessive-Compulsive Disordered Patients at Rest
  141. Schizophrenic auditory hallucinations are associated with increased regional cerebral blood flow during verbal memory activation in a study using single photon emission computed tomography
  142. Immunoscintigraphy with a 99Tcm-labelled anti-granulcyte monoclonal antibody in patients with human immunodeficiency virus infection and AIDS
  143. Brain Perfusion Abnormalities in Gilles de la Tourette's Syndrome
  144. Technetium-99m-L,L-ethylenedicysteine scintigraphy in patients with renal disorders
  145. Optimised interictal HMPAO-SPECT in the evaluation of partial epilepsies
  146. Clinical brain radionuclide imaging studies
  147. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls
  148. Differentiation between Alzheimer's disease and multi‐infarct dementia: Spect vs MR imaging
  149. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123I-IBZM single photon emission tomography (SPET) study
  150. In vivo imaging of GABAA receptors using sequential whole-volume iodine-123 iomazenil single-photon emission tomography
  151. Dopamine receptor availability in Tourette's Syndrome
  152. Dopamine receptor availability in Tourette's syndrome
  153. Recognition of Mental State Terms
  154. Clinical experience with a multidetector SPET system (Toshiba GCA-9300A)
  155. Chronic fatigue syndrome Role of psychological factors overemphasised
  156. Stereotypy, schizophrenia and dopamine D2 receptor binding in the basal ganglia
  157. Regional cerebral blood flow (rCBF) in schizophrenia during verbal memory activation: a 99mTc-HMPAO single photon emission tomography (SPET) study
  158. Striatal dopamine receptor binding in epileptic psychoses
  159. HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.
  160. D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients
  161. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone
  162. 99mTc-HMPAO single photon emission tomography in late life depression: a pilot study of regional cerebral blood flow at rest and during a verbal fluency task
  163. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study
  164. Elevated frontal cerebral blood flow in Gilles de la Tourette syndrome: A 99Tcm-HMPAO SPECT study
  165. Assessment of myocardial viability with 201T1 SPET and reinjection technique
  166. Demonstration of human motor cortex activation using SPECT
  167. Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.
  168. rCBF abnormalities detected, and sequentially followed, by SPECT in neuro-Behcet's syndrome with normal CT and MRI imaging
  169. Cerebral Blood Flow Abnormalities in Adults with Infantile Autism
  170. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia
  171. Vasodilator myocardial perfusion imaging: demonstration of local electrophysiological changes of ischaemia
  172. Postviral fatigue syndrome.
  173. SPECT in epilepsy
  174. Physical assessment of the GE/CGR Neurocam and comparison with a single rotating gamma-camera
  175. Diagnosing Alzheimer's disease.
  176. Thallium Myocardial Perfusion Tomography in Clinical Cardiology
  177. Clinical Applications
  178. Clinical Case Material
  179. Image Interpretation
  180. Imaging Techniques
  181. Introduction
  182. Radiopharmaceuticals
  183. Stress Techniques
  184. The Future
  185. Endocardial monophasic action potential recordings for the detection of muocardial ischemia in man: A study using atrial pacing stress and myocardial perfusion scintigraphy
  186. Single photon emission tomography in Alzheimer's disease. A longitudinal study of changes in relative regional cerebral blood flow
  187. Single photon emission tomography in growth-hormone related Creutzfeldt-Jakob disease
  188. Diagnosis of brain death with technetium 99m hexamethylpropylene amine oxime
  189. The use of cerebral activation procedures with single photon emission tomography
  190. 99TCm-HMPAO SPECT studies in traumatic intracerebral haematoma.
  191. A Historical and Philosophical Review of Localizing Brain Function
  192. Activation Protocols in Normal Subjects Using SPET: A Window into Normal Brain Function
  193. Activation Studies in Specific Disease States: Future Applications
  194. Clinical Use of SPET Imaging in Psychiatric and Neurological Disease
  195. Description and Principles of Neuroactivation
  196. Models of Brain Processing with Respect to Functional Neuroimaging
  197. Neuroactivation and Neuroimaging with SPET
  198. Principles of Emission Tomography
  199. Radiopharmaceutical Ligands and Tracers
  200. Review of Previous SPET Neuroactivation Studies in Normal Controls
  201. SPET Instrumentation: Characteristics and New Developments
  202. The use of cerebral activation procedures with single photon emission tomography
  203. In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans
  204. Single photon emission tomography (SPET) with 99Tc m-hexamethylpropyleneamineoxime (HMPAO) in research and clinical practice - a useful tool
  205. Regional cerebral blood flow (rCBF) during migraine using 99mTc-hexamethylpropyleneamineoxime (99mTc-HMPAO) and single photon emission tomography (SPET)
  206. 99Tcm-HMPAO SPET and cerebral blood flow
  207. Intracellular localization of 99Tcm-d, 1-HMPAO and 201T1-DDC in rat brain
  208. DIAGNOSIS OF HERPES SIMPLEX ENCEPHALITIS BY SINGLE PHOTON EMISSION TOMOGRAPHY
  209. ROLE OF ROUTINE FUNCTIONAL BRAIN IMAGING IN TEMPORAL LOBE EPILEPSY
  210. 99mTc-HMPAO WASHOUT FROM BRAIN
  211. Technetium-99m Pentavalent DMSA Imaging Detects Metastases of Poorly Differentiated Carcinoma of the Thyroid
  212. The investigation of Alzheimer's disease with single photon emission tomography.
  213. 99mTc-HMPAO WASHOUT IN PROGNOSIS OF STROKE
  214. White cells radiolabelled with 111IN AND 99Tcm- a study of relative sensitivity and in vivo viability
  215. RADIONUCLIDE IMAGING OF SCROTUM
  216. TRANSIENT LEUCOPENIA INDUCED BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
  217. IMAGING CEREBRAL DAMAGE IN HIV INFECTION
  218. Functional imaging of the brain
  219. Stress induced right ventricular dysfunction: An indication of reversible right ventricular ischaemia
  220. The in vivo distribution of 99Tcm-HM-PAO in normal man
  221. REGULAR CEREBRAL BLOOD FLOW MAPPING WITH 99mTc-LABELLED COMPOUND